Abstract
In North America, Lyme disease (LD) is primarily caused by the spirochetal bacterium Borrelia burgdorferi, transmitted to humans by Ixodes species tick bites, at an estimated rate of 476,000 patients diagnosed per year. Acute LD often manifests with flu-like symptoms and an expanding rash known as erythema migrans (EM) and less often with neurologic, neuropsychiatric, arthritic, or cardiac features. Most acute cases of Lyme disease are effectively treated with antibiotics, but 10–20% of individuals may experience recurrent or persistent symptoms. This chapter focuses on the neuropsychiatric aspects of Lyme disease, as these are less widely recognized by physicians and often overlooked. Broader education about the potential complexity, severity, and diverse manifestations of tick-borne diseases is needed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Adams WV, Rose CD, Eppes SC, Klein JD (1994) Cognitive effects of Lyme disease in children. Pediatrics 94(2 Pt 1):185–189
Adams WV, Rose CD, Eppes SC, Klein JD (1999) Cognitive effects of Lyme disease in children: a 4 year followup study. J Rheumatol 26(5):1190–1194
Adrion ER, Aucott J, Lemke KW, Weiner JP (2015) Health care costs, utilization and patterns of care following Lyme disease. PLoS One 10(2):e0116767. https://doi.org/10.1371/journal.pone.0116767
Aguero-Rosenfeld ME, Wang G, Schwartz I, Wormser GP (2005) Diagnosis of Lyme borreliosis. Clin Microbiol Rev 18(3):484–509. https://doi.org/10.1128/CMR.18.3.484-509.2005
Alaedini A, Latov N (2005) Antibodies against OspA epitopes of Borrelia burgdorferi cross-react with neural tissue. J Neuroimmunol 159(1–2):192–195. https://doi.org/10.1016/j.jneuroim.2004.10.014
Aucott JN (2015) Posttreatment Lyme disease syndrome. Infect Dis Clin North Am 29(2):309–323. https://doi.org/10.1016/j.idc.2015.02.012
Aucott JN, Rebman AW (2021) Long-haul COVID: heed the lessons from other infection-triggered illnesses. Lancet 397(10278):967–968
Aucott JN, Morrison C, Munoz B, Rowe P, Schwarzwalder A, West S (2009) Diagnostic challenges of early Lyme disease: lessons from a community case series. BMC Infect Dis
Aucott JN, Crowder LA, Yedlin V, Kortte KB (2012) Bull’s-eye and nontarget skin lesions of Lyme disease: an internet survey of identification of erythema migrans. Dermatol Res Pract 2012:451727. https://doi.org/10.1155/2012/451727
Aucott JN, Soloski MJ, Rebman AW et al (2016) CCL19 as a chemokine risk factor for posttreatment Lyme disease syndrome: a prospective clinical cohort study. Clin Vaccine Immunol 23(9):757–766. https://doi.org/10.1128/CVI.00071-16
Betman AL, Iyer M, Coyle PK, Dattwyler RJ (1993) Neurologic manifestations in children with north American Lyme disease. Neurology 43
Bloch EM, Kumar S, Krause PJ (2019) Persistence of Babesia microti infection in humans. Pathogens 8(3). https://doi.org/10.3390/pathogens8030102
Bolton S, Warner J, Harriss E, Geddes J, Saunders KEA (2021) Bipolar disorder: trimodal age-at-onset distribution. Bipolar Disord 23(4):341–356. https://doi.org/10.1111/bdi.13016
Bransfield RC (2017) Suicide and Lyme and associated diseases. Neuropsychiatr Dis Treat 13:1575–1587. https://doi.org/10.2147/NDT.S136137
Breitschwerdt EB, Greenberg R, Maggi RG, Mozayeni BR, Lewis A, Bradley JM (2019) Bartonella henselae bloodstream infection in a boy with pediatric acute-onset neuropsychiatric syndrome. J Cent Nerv Syst Dis 11:1179573519832014. https://doi.org/10.1177/1179573519832014
Burgdorfer W (1989) Vector/host relationships of the Lyme disease spirochete, Borrelia burgdorferi. Rheum Dis Clin North Am 15(4):775–787
Cameron DJ, Johnson LB, Maloney EL (2014) Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease. Expert Rev Anti Infect Ther 12(9):1103–1135. https://doi.org/10.1586/14787210.2014.940900
Çelik T, Çelik Ü, Kömür M, Tolunay O, Dönmezer Ç, Yıldızdas D (2016) Treatment of Lyme neuroborreliosis with plasmapheresis. J Clin Apher 31(5):476–478. https://doi.org/10.1002/jca.21430
Centers for Disease Control and Prevention (2022) Lyme disease data and surveillance. Published. https://www.cdc.gov/lyme/datasurveillance/index.html
Centers for Disease Control and Prevention (n.d.) Lyme disease diagnosis and testing. https://www.cdc.gov/lyme/stats/humancases.html
Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) D of VBD (DVBD) (2022a) Lyme disease. Published. https://www.cdc.gov/lyme/index.html
Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) D of VBD (DVBD) (2022b) Treatment of Lyme disease. Published. Accessed 1 Aug 2022. https://www.cdc.gov/lyme/treatment/index.html
Chandra A, Wormser GP, Klempner MS et al (2010) Anti-neural antibody reactivity in patients with a history of Lyme borreliosis and persistent symptoms. Brain Behav Immun 24(6):1018–1024. https://doi.org/10.1016/j.bbi.2010.03.002
Chaudhry IB, Hallak J, Husain N et al (2012) Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol 26(9):1185–1193. https://doi.org/10.1177/0269881112444941
Coughlin JM, Yang T, Rebman AW et al (2018) Imaging glial activation in patients with post-treatment Lyme disease symptoms: a pilot study using [11C]DPA-713 PET. J Neuroinflammation 15(1):346. https://doi.org/10.1186/s12974-018-1381-4
Cross A, Bouboulis D, Shimasaki C, Jones CR (2021) Case report: PANDAS and persistent Lyme disease with neuropsychiatric symptoms: treatment, resolution, and recovery. Front Psych 12:505941. https://doi.org/10.3389/fpsyt.2021.505941
Cunningham MW (2014) Rheumatic fever, autoimmunity, and molecular mimicry: the streptococcal connection. Int Rev Immunol 33(4):314–329. https://doi.org/10.3109/08830185.2014.917411
Danieli MG, Piga MA, Paladini A et al (2021) Intravenous immunoglobulin as an important adjunct in the prevention and therapy of coronavirus 2019 disease. Scand J Immunol 94(5):e13101. https://doi.org/10.1111/sji.13101
Daskalakis D (2017) Advisory #14: tick-borne disease advisory
Dattwyler RJ, Volkman DJ, Luft BJ, Halperin JJ, Thomas J, Golightly MG (1988) Seronegative Lyme disease: dissociation of specific T- and B-lymphocyte responses to Borrelia burgdorferi. N Engl J Med 319(22):1441–1446. https://doi.org/10.1056/NEJM198812013192203
Delaney SL, Murray LA, Aasen CE, Bennett CE, Brown E, Fallon BA (2020) Borrelia miyamotoi serology in a clinical population with persistent symptoms and suspected tick-borne illness. Front Med 7:567350. https://doi.org/10.3389/fmed.2020.567350
DeLong A, Hsu M, Kotsoris H (2019) Estimation of cumulative number of post-treatment Lyme disease cases in the US, 2016 and 2020. BMC Public Health:19. https://doi.org/10.1186/s12889-019-6681-9
Dersch R, Sarnes AA, Maul M et al (2015) Quality of life, fatigue, depression and cognitive impairment in Lyme neuroborreliosis. J Neurol 262(11):2572–2577
Doshi S, Keilp JG, Strobino B, McElhiney M, Rabkin J, Fallon BA (2018) Depressive symptoms and suicidal ideation among symptomatic patients with a history of Lyme disease vs two comparison groups. Psychosomatics 59(5):481–489. https://doi.org/10.1016/j.psym.2018.02.004
Dressler F, Whalen JA, Reinhardt BN, Steere AC (1993) Western blotting in the serodiagnosis of Lyme disease. J Infect Dis 167(2):392–400. https://doi.org/10.1093/infdis/167.2.392
Emadi-Kouchak H, Mohammadinejad P, Asadollahi-Amin A et al (2016) Therapeutic effects of minocycline on mild-to-moderate depression in HIV patients: a double-blind, placebo-controlled, randomized trial. Int Clin Psychopharmacol 31(1):20–26. https://doi.org/10.1097/YIC.0000000000000098
Embers ME, Barthold SW, Borda JT et al (2012) Persistence of Borrelia burgdorferi in rhesus macaques following antibiotic treatment of disseminated infection. PLoS One 7(1):e29914. https://doi.org/10.1371/journal.pone.0029914
Fallon BA (2012) A reappraisal of the U.S. clinical trials of post-treatment Lyme disease syndrome. Open Neurol J 6(1):79–87. https://doi.org/10.2174/1874205x01206010079
Fallon BA, Neilds JA (1994) Lyme disease: a neuropsychiatric illness. Am J Psychiatry 151(11):1571–1583
Fallon BA, Sotsky J (2018) Conquering Lyme disease: science bridges the great divide. Columbia University Press
Fallon BA, Das S, Plutchok JJ, Tager F, Liegner KB, Van Heertum R (1997) Functional brain imaging and neuropsychological testing in Lyme disease. Clin Infect Dis:57–63
Fallon BA, Keilp JG, Corbera KM et al (2008) A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology 70(13):992–1003. https://doi.org/10.1212/01.WNL.0000284604.61160.2d
Fallon BA, Lipkin RB, Corbera KM et al (2009) Regional cerebral blood flow and metabolic rate in persistent Lyme encephalopathy. Arch Gen Psychiatry 66(5):554–563. https://doi.org/10.1001/archgenpsychiatry.2009.29
Fallon BA, Pavlicova M, Coffino S, Brenner C (2014) A comparison of Lyme disease serologic test results from 4 laboratories in patients with persistent symptoms after antibiotic treatment. Clin Infect Dis 59(12):1705–1710
Fallon BA, Strobino B, Reim S, Stoner J, Cunningham MW (2020) Anti-lysoganglioside and other anti-neuronal autoantibodies in post-treatment Lyme Disease and Erythema Migrans after repeat infection. Brain Behav Immun Health:100015. https://doi.org/10.1016/j.bbih.2019.100015
Fallon BA, Madsen T, Erlangsen A, Benros ME (2021) Lyme borreliosis and associations with mental disorders and suicidal behavior: a nationwide Danish cohort study. Am J Psychiatry 178(10):921–931. https://doi.org/10.1176/appi.ajp.2021.20091347
Feng J, Zhang S, Shi W, Zubcevik N, Miklossy J, Zhang Y (2017) Selective essential oils from spice or culinary herbs have high activity against stationary phase and biofilm Borrelia burgdorferi. Front Med 4:169. https://doi.org/10.3389/fmed.2017.00169
Feng J, Li T, Yee R et al (2019) Stationary phase persister/biofilm microcolony of Borrelia burgdorferi causes more severe disease in a mouse model of Lyme arthritis: implications for understanding persistence, post-treatment Lyme disease syndrome (PTLDS), and treatment failure. Discov Med 27(148):125–138
Feng J, Leone J, Schweig S, Zhang Y (2020) Evaluation of natural and botanical medicines for activity against growing and non-growing forms of B. burgdorferi. Front Med 7:6. https://doi.org/10.3389/fmed.2020.00006
Frankovich J, Thienemann M, Rana S, Chang K (2015) Five youth with pediatric acute-onset neuropsychiatric syndrome of differing etiologies. J Child Adolesc Psychopharmacol 25(1):31–37. https://doi.org/10.1089/cap.2014.0056
Frankovich J, Swedo S, Murphy T et al (2017) Clinical management of pediatric acute-onset neuropsychiatric syndrome: part II – use of immunomodulatory therapies. J Child Adolesc Psychopharmacol 27(7):574–593. https://doi.org/10.1089/cap.2016.0148
Frick LR, Rapanelli M, Jindachomthong K et al (2018) Differential binding of antibodies in PANDAS patients to cholinergic interneurons in the striatum. Brain Behav Immun 69:304–311. https://doi.org/10.1016/j.bbi.2017.12.004
Gadila SKG, Rosoklija G, Dwork AJ, Fallon BA, Embers ME (2021) Detecting Borrelia spirochetes: a case study with validation among autopsy specimens. Front Neurol 12:628045. https://doi.org/10.3389/fneur.2021.628045
Gao J, Gong Z, Montesano D, Glazer E, Liegner K (2020) “Repurposing” disulfiram in the treatment of Lyme disease and babesiosis: retrospective review of first 3 years’ experience in one medical practice. Antibiotics 9(12). https://doi.org/10.3390/antibiotics9120868
García Moncó JC, Wheeler CM, Benach JL et al (1993) Reactivity of neuroborreliosis patients (Lyme disease) to cardiolipin and gangliosides. J Neurol Sci 117(1–2):206–214
Garcia-Monco JC, Seidman RJ, Benach JL (1995) Experimental immunization with Borrelia burgdorferi induces development of antibodies to gangliosides. Infect Immun 63(10):4130–4137
Hamer S, Goldberg T, Kitron U et al (2012) Wild birds and urban ecology of ticks and tick-borne pathogens, Chicago, Illinois, USA, 2005-2010. Emerg Infect Dis 18:1589–1595. https://doi.org/10.3201/eid1810.120511
Han S, Lubelczyk C, Hickling GJ, Belperron AA, Bockenstedt LK, Tsao JI (2019) Vertical transmission rates of Borrelia miyamotoi in Ixodes scapularis collected from white-tailed deer. Ticks Tick Borne Dis 10(3):682–689. https://doi.org/10.1016/j.ttbdis.2019.02.014
Hartung HP (2008) Advances in the understanding of the mechanism of action of IVIg. J Neurol 255(Suppl):3–6. https://doi.org/10.1007/s00415-008-3002-0
Hassett AL, Radvanski DC, Buyske S et al (2008) Role of psychiatric comorbidity in chronic Lyme disease. Arthritis Care Res 59(12):1742–1749. https://doi.org/10.1002/art.24314
Hatfield E, Phillips K, Swidan S, Ashman L (2020) Use of low-dose naltrexone in the management of chronic pain conditions: a systematic review. J Am Dent Assoc 151(12):891–902.e1. https://doi.org/10.1016/j.adaj.2020.08.019
Hayward J, Sanchez J, Perry A et al (2017) Ticks from diverse genera encode chemokine-inhibitory evasin proteins. J Biol Chem 292(38):15670–15680. https://doi.org/10.1074/jbc.M117.807255
Hess A, Buchmann J, Zettl UK et al (1999) Borrelia burgdorferi central nervous system infection presenting as an organic schizophrenialike disorder. Biol Psychiatry 45(6):795. https://doi.org/10.1016/S0006-3223(98)00277-7
Hodzic E, Feng S, Holden K, Freet KJ, Barthold SW (2008) Persistence of Borrelia burgdorferi following antibiotic treatment in mice. Antimicrob Agents Chemother 52(5):1728–1736. https://doi.org/10.1128/AAC.01050-07
Horowitz RI, Freeman PR (2019) Precision medicine: retrospective chart review and data analysis of 200 patients on dapsone combination therapy for chronic Lyme disease/post-treatment Lyme disease syndrome: part 1. Int J Gen Med 12:101–119. https://doi.org/10.2147/IJGM.S193608
Johnson L, Wilcox S, Mankoff J, Stricker RB (2014) Severity of chronic Lyme disease compared to other chronic conditions: a quality of life survey. PeerJ 2014(1):1–21. https://doi.org/10.7717/peerj.322
Kalish RA, Kaplan RF, Taylor E, Jones-Woodward L, Workman K, Steere AC (2001) Evaluation of study patients with Lyme disease, 10–20-year follow-up. J Infect Dis 183(3):453–460. https://doi.org/10.1086/318082
Katz A, Berkley J (2009) Diminished epidermal nerve fiber density in patients with antibodies to outer surface protein A (OspA) of B. burgdorferi improves with intravenous immunoglobulin therapy. J Neurol:72
Keilp JG, Corbera K, Gorlyn M, Oquendo MA, Mann JJ, Fallon BA (2019) Neurocognition in post-treatment Lyme disease and major depressive disorder. Arch Clin Neuropsychol 34(4):466–480. https://doi.org/10.1093/arclin/acy083
Kim PS, Fishman MA (2020) Low-dose naltrexone for chronic pain: update and systemic review. Curr Pain Headache Rep 24(10):64. https://doi.org/10.1007/s11916-020-00898-0
Kirvan CA, Swedo SE, Heuser JS, Cunningham MW (2003) Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nat Med 9(7):914–920. https://doi.org/10.1038/nm892
Klempner MS, Evans J, Schmid CH et al (2001) Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 345(2):85–92
Knudtzen FC, Andersen NS, Jensen TG, Skarphédinsson S (2017) Characteristics and clinical outcome of Lyme neuroborreliosis in a high endemic area, 1995-2014: a retrospective cohort study in Denmark. Clin Infect Dis 65(9):1489–1495. https://doi.org/10.1093/cid/cix568
Krupp LB, Masur D, Schwartz J et al (1991) Cognitive functioning in late Lyme borreliosis. Arch Neurol 48(11):1125–1129. https://doi.org/10.1001/archneur.1991.00530230033017
Krupp LB, Hyman LG, Grimson R et al (2003) Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology 60(12):1923–1930. Accessed 25 Mar 2019. http://www.ncbi.nlm.nih.gov/pubmed/12821734
Kugeler KJ, Schwartz AM, Delorey MJ, Mead PS, Hinckley AF (2021) Estimating the frequency of Lyme disease diagnoses, United States, 2010-2018. Emerg Infect Dis 27(2):616–619. https://doi.org/10.3201/eid2702.202731
Kumar R, Basu A, Sinha S et al (2016) Role of oral minocycline in acute encephalitis syndrome in India – a randomized controlled trial. BMC Infect Dis 16:67. https://doi.org/10.1186/s12879-016-1385-6
Lantos PM, Rumbaugh J, Bockenstedt LK et al (2021) Clinical practice guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 guidelines for the prevention, diagnosis and treatment of Lyme disease. Clin Infect Dis 72(1):e1–e48. https://doi.org/10.1093/cid/ciaa1215
Lashnits E, Maggi R, Jarskog F, Bradley J, Breitschwerdt E, Frohlich F (2021) Schizophrenia and Bartonella spp. infection: a pilot case-control study. Vector-Borne Zoonotic Dis 21(6):413–421. https://doi.org/10.1089/vbz.2020.2729
Lawrence C, Lipton RB, Lowy FD, Coyle PK (1995) Seronegative chronic relapsing neuroborreliosis. Eur Neurol 35(2):113–117. https://doi.org/10.1159/000117104
Leimer N, Wu X, Imai Y et al (2021) A selective antibiotic for Lyme disease. Cell 184(21):5405–5418.e16. https://doi.org/10.1016/j.cell.2021.09.011
Liang L, Wang J, Schorter L et al (2020) Rapid clearance of Borrelia burgdorferi from the blood circulation. Parasit Vectors 13(1):191. https://doi.org/10.1186/s13071-020-04060-y
Liegner KB (1993) Lyme disease: the sensible pursuit of answers. J Clin Microbiol 31(8):1961–1963. https://doi.org/10.1128/jcm.31.8.1961-1963.1993
Liegner KB, Duray P, Agricola M et al (1997) Lyme disease and the clinical spectrum of antibiotic responsive chronic meningoencephalomyelitides. J Spirochetal Tick Borne Dis 4:61–73
Lochhead RB, Strle K, Arvikar SL, Weis JJ, Steere AC (2021) Lyme arthritis: linking infection, inflammation and autoimmunity. Nat Rev Rheumatol 17(8):449–461. https://doi.org/10.1038/s41584-021-00648-5
Locke JW (2019) Evasion in Borrelia spirochetes: mechanisms and opportunities for intervention. Antibiotics (Basel) 8(2):80
Logigian EL, Kaplan RF, Steere AC (1990) Chronic neurologic manifestations of Lyme disease. N Engl J Med 323(21):1438–1444. https://doi.org/10.1056/NEJM199011223232102
Logigian EL, Johnson KA, Kijewski MF et al (1997) Reversible cerebral hypoperfusion in Lyme encephalopathy. Neurology 49(6):1661–1670. https://doi.org/10.1212/wnl.49.6.1661
Marques A (2008) Chronic Lyme disease: a review. Tick-borne Dis Part I Lyme Dis 22(2):341–360. https://doi.org/10.1016/j.idc.2007.12.011
Marques AR (2015) Laboratory diagnosis of Lyme disease: advances and challenges. Infect Dis Clin North Am 29(2):295–307. https://doi.org/10.1016/j.idc.2015.02.005
Mead P, Petersen J, Hinckley A (2019) Updated CDC recommendation for serologic diagnosis of Lyme disease. Morb Mortal Wkly Rep 68(32):703
Melamed I, Kobayashi RH, O’Connor M et al (2021) Evaluation of intravenous immunoglobulin in pediatric acute-onset neuropsychiatric syndrome. J Child Adolesc Psychopharmacol 31(2):118–128. https://doi.org/10.1089/cap.2020.0100
Merrell DS, Falkow S (2004) Frontal and stealth attack strategies in microbial pathogenesis. Nature 430(6996):250–256. https://doi.org/10.1038/nature02760
Miles S, Mansuria S (2021) Lyme disease mimics postoperative cellulitis. J Minim Invasive Gynecol 28(5):931–932
Murphy T, Storch E, Strawser M, Priyal Patel BA (2006) Selective serotonin reuptake inhibitor-induced behavioral activation in the PANDAS subtype. Prim Psychiatry:13
Mustafiz F, Moeller J, Kuvaldina M, Bennett C, Fallon BA (2022) Persistent symptoms, Lyme disease, and prior trauma. J Nerv Ment Dis 210(5):359–364. https://doi.org/10.1097/NMD.0000000000001452
National Institute for Health and Care Excellence (2018) Lyme disease (NICE Guideline NG95) https://www.nice.org.uk/guidance/NG95
Nields JA, Fallon BA, Jastreboff PJ (1999) Carbamazepine in the treatment of Lyme disease-induced hyperacusis. J Neuropsychiatry Clin Neurosci 11(1):97–99. https://doi.org/10.1176/jnp.11.1.97
Novak P, Felsenstein D, Mao C, Octavien NR, Zubcevik N (2019) Association of small fiber neuropathy and post treatment Lyme disease syndrome. PLoS One 14(2):e0212222. https://doi.org/10.1371/journal.pone.0212222
O’Kelly B, Vidal L, McHugh T, Woo J, Avramovic G, Lambert JS (2022) Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. Brain Behav Immun Health 24:100485. https://doi.org/10.1016/j.bbih.2022.100485
Oczko-Grzesik B, Kępa L, Puszcz-Matlińska M et al (2017) Estimation of cognitive and affective disorders occurrence in patients with Lyme borreliosis. Ann Agric Environ Med 24(1):33–38
Owens B (2022) How “long covid” is shedding light on postviral syndromes. BMJ 378:o2188. https://doi.org/10.1136/bmj.o2188
Pachner AR (1988) Borrelia burgdorferi in the nervous system: the new “great imitator”. Ann N Y Acad Sci 539(1):56–64. https://doi.org/10.1111/j.1749-6632.1988.tb31838.x
Pachner AR, Steiner I (2007) Lyme neuroborreliosis: infection, immunity, and inflammation. Lancet Neurol 6(6):544–552. https://doi.org/10.1016/S1474-4422(07)70128-X
Parkitny L, Younger J (2017) Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia. Biomedicine 5(2). https://doi.org/10.3390/biomedicines5020016
Pasareanu AR, Mygland Å, Kristensen Ø (2012) A woman in her 50s with manic psychosis. Tidsskr Nor Laegeforen 132(5):537–539. https://doi.org/10.4045/TIDSSKR.11.0683
Platt MP, Bolding KA, Wayne CR et al (2020) Th17 lymphocytes drive vascular and neuronal deficits in a mouse model of postinfectious autoimmune encephalitis. Proc Natl Acad Sci U S A 117(12):6708–6716. https://doi.org/10.1073/pnas.1911097117
Pothineni VR, Wagh D, Babar MM et al (2016) Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening. Drug Des Devel Ther 10:1307–1322. https://doi.org/10.2147/DDDT.S101486
Prince HE, Lapé-Nixon M, Patel H, Yeh C (2010) Comparison of the Babesia duncani (WA1) IgG detection rates among clinical sera submitted to a reference laboratory for WA1 IgG testing and blood donor specimens from diverse geographic areas of the United States. Clin Vaccine Immunol 17(11):1729–1733. https://doi.org/10.1128/CVI.00256-10
Raveche ES, Schutzer SE, Fernandes H et al (2005) Evidence of Borrelia autoimmunity-induced component of Lyme carditis and arthritis. J Clin Microbiol 43(2):850–856. https://doi.org/10.1128/JCM.43.2.850-856.2005
Rebman AW, Bechtold KT, Yang T et al (2017) The clinical, symptom, and quality-of-life characterization of a well-defined group of patients with posttreatment Lyme disease syndrome. Front Med 4:224. https://doi.org/10.3389/fmed.2017.00224
Reik L, Steere AC, Bartenhagen NH, Shopc RE, Malawista SE (1979) Neurologic abnormalities of Lyme disease. Medicine (Baltimore) 58:281–294
Riedel M, Straube A, Schwarz MJ, Wilske B, Muller N (1998) Lyme disease presenting as Tourette’s syndrome. Lancet 351(9100):418–419. https://doi.org/10.1016/S0140-6736(05)78357-4
Rupprecht TA, Koedel U, Angele B, Fingerle V, Pfister HW (2006) Cytokine CXCL13 – a possible early CSF marker for neuroborreliosis. Nervenarzt 77(4):470–473. https://doi.org/10.1007/s00115-005-2021-7
Sanchez-Vicente S, Tagliafierro T, Coleman JL, Benach JL, Tokarz R (2019) Polymicrobial nature of tick-borne diseases. MBio 10:5
Schmidt H, Djukic M, Jung K et al (2015) Neurocognitive functions and brain atrophy after proven neuroborreliosis: a case-control study. BMC Neurol 15:article 139
Schutzer SE, Coyle PK, Belman AL, Golightly MG, Drulle J (1990) Sequestration of antibody to Borrelia burgdorferi in immune complexes in seronegative Lyme disease. Lancet 335(8685):312–315
Schutzer SE, Coyle PK, Reid P, Holland B (1999) Borrelia burgdorferi-specific immune complexes in acute Lyme disease. JAMA 282(20):1942–1946
Schutzer SE, Berger B, Krueger J, Eshoo M, Ecker D, Aucott JN (2013) Atypical erythema migrans in patients with PCR-positive Lyme disease. Emerg Infect Dis 19(5):815–817
Scott JD, Scott CM (2018) Human babesiosis caused by Babesia duncani has widespread distribution across Canada. Healthcare (Basel) 6(2). https://doi.org/10.3390/healthcare6020049
Sharma B, Brown AV, Matluck NE, Hu LT, Lewis K (2015) Borrelia burgdorferi, the causative agent of Lyme disease, forms drug-tolerant persister cells. Antimicrob Agents Chemother 59(8):4616–4624. https://doi.org/10.1128/AAC.00864-15
Sigal LH (1993) Cross-reactivity between Borrelia burgdorferi Flagellin and a human axonal 64,000 molecular weight protein. J Infect Dis 167(6):1372–1378. https://doi.org/10.1093/infdis/167.6.1372
Skare JT, Garcia BL (2020) Complement evasion by Lyme disease spirochetes. Trends Microbiol 28(11):889–899. https://doi.org/10.1016/j.tim.2020.05.004
Smith R, Schoen R, Rahn D et al (2002) Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. Ann Intern Med 136(6):421–428
Soin A, Soin Y, Dann T et al (2021) Low-dose naltrexone use for patients with chronic regional pain syndrome: a systematic literature review. Pain Physician 24(4):E393–E406
Soloski MJ, Crowder LA, Lahey LJ, Wagner CA, Robinson WH, Aucott JN (2014) Serum inflammatory mediators as markers of human Lyme disease activity. PLoS One 9(4):e93243. https://doi.org/10.1371/journal.pone.0093243
Sonneville R, Klein I, de Broucker T, Wolff M (2009) Post-infectious encephalitis in adults: diagnosis and management. J Infect 58(5):321–328. https://doi.org/10.1016/j.jinf.2009.02.011
Steere AC (2020) Posttreatment Lyme disease syndromes: distinct pathogenesis caused by maladaptive host responses. J Clin Invest 130(5):2148–2151. https://doi.org/10.1172/JCI138062
Steere AC, Angelis SM (2006) Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. Arthritis Rheum 54(10):3079–3086. https://doi.org/10.1002/art.22131
Straubinger RK, Summers BA, Chang YF, Appel MJ (1997) Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment. J Clin Microbiol 35(1):111–116. https://doi.org/10.1128/jcm.35.1.111-116.1997
Strle F, Maraspin V, Lotric-Furlan S, Ruzić-Sabljić E, Cimperman J (1996) Azithromycin and doxycycline for treatment of Borrelia culture-positive erythema migrans. Infection 24(1):64–68. https://doi.org/10.1007/BF01780661
Strle K, Stupica D, Drouin EE, Steere AC, Strle F (2014) Elevated levels of IL-23 in a subset of patients with post-Lyme disease symptoms following erythema migrans. Clin Infect Dis 58(3):372–380. https://doi.org/10.1093/cid/cit735
Strle K, Sulka KB, Pianta A et al (2017) T-helper 17 cell cytokine responses in Lyme disease correlate with Borrelia burgdorferi antibodies during early infection and with autoantibodies late in the illness in patients with antibiotic-refractory Lyme arthritis. Clin Infect Dis 64(7):930–938. https://doi.org/10.1093/CID/CIX002
Swedo SE, Leonard HL, Garvey M et al (1998) Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry 155(2):264–271. https://doi.org/10.1176/ajp.155.2.264
Syngle A, Verma I, Krishan P, Garg N, Syngle V (2014) Minocycline improves peripheral and autonomic neuropathy in type 2 diabetes: MIND study. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol 35(7):1067–1073. https://doi.org/10.1007/s10072-014-1647-2
Tager FA, Fallon BA, Keilp J et al (2001) A controlled study of cognitive deficits in children with chronic Lyme disease. J Neuropsychiatry Clin Neurosci 13(4):500–507. https://doi.org/10.1176/jnp.13.4.500
Tetens MM, Haahr R, Dessau RB et al (2021) Assessment of the risk of psychiatric disorders, use of psychiatric hospitals, and receipt of psychiatric medication among patients with Lyme neuroborreliosis in Denmark. JAMA Psychiat 78(2):177–186. https://doi.org/10.1001/jamapsychiatry.2020.2915
Tibbles C, Edlow J (2007) Does this patient have erythema migrans? JAMA 297(23):2617–2627
Uhde M, Ajamian M, Li X, Wormser GP, Marques A, Alaedini A (2016) Expression of C-reactive protein and serum amyloid A in early to late manifestations of Lyme disease. Clin Infect Dis 63(11):1399–1404. https://doi.org/10.1093/cid/ciw599
Uhde M, Indart A, Fallon BA et al (2018) C-reactive protein response in patients with post-treatment Lyme disease symptoms versus those with myalgic encephalomyelitis/chronic fatigue syndrome. Clin Infect Dis 67(8):1309–1310. https://doi.org/10.1093/cid/ciy299
Vannier EG, Diuk-Wasser MA, Ben Mamoun C, Krause PJ (2015) Babesiosis. Infect Dis Clin North Am 29(2):357–370. https://doi.org/10.1016/j.idc.2015.02.008
Vrethem M, Hellblom L, Widlund M et al (2002) Chronic symptoms are common in patients with neuroborreliosis – a questionnaire follow-up study. Acta Neurol Scand 106(4):205–208. https://doi.org/10.1034/j.1600-0404.2002.01358.x
Waniek C, Prohovnik I, Kaufman MA, Dwork AJ (1995) Rapidly progressive frontal-type dementia associated with Lyme disease. J Neuropsychiatry Clin Neurosci 7(3):345–347. https://doi.org/10.1176/jnp.7.3.345
Weissenbacher S, Ring J, Hofmann H (2005) Gabapentin for the symptomatic treatment of chronic neuropathic pain in patients with late-stage Lyme borreliosis: a pilot study. Dermatology 211(2):123–127. https://doi.org/10.1159/000086441
Wong KH, Shapiro ED, Soffer GK (2022) A review of post-treatment Lyme disease syndrome and chronic Lyme disease for the practicing immunologist. Clin Rev Allergy Immunol 62(1):264–271. https://doi.org/10.1007/s12016-021-08906-w
Wormser GP, Schriefer M, Aguero-Rosenfeld ME (2013) Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease. Diagn Microbiol Infect Dis 75(1):9–15
Xu J, Liu RJ, Fahey S et al (2021) Antibodies from children with PANDAS bind specifically to striatal cholinergic interneurons and alter their activity. Am J Psychiatry 178(1):48–64. https://doi.org/10.1176/appi.ajp.2020.19070698
Younger J, Noor N, McCue R, Mackey S (2013) Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum 65(2):529–538. https://doi.org/10.1002/art.37734
Younger J, Parkitny L, McLain D (2014) The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol 33(4):451–459. https://doi.org/10.1007/s10067-014-2517-2
Zhang Y, Alvarez-Manzo H, Leone J, Schweig S, Zhang Y (2021) Botanical medicines Cryptolepis sanguinolenta, Artemisia annua, Scutellaria baicalensis, Polygonum cuspidatum, and Alchornea cordifolia demonstrate inhibitory activity against Babesia duncani. Front Cell Infect Microbiol 11:624745. https://doi.org/10.3389/fcimb.2021.624745
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Delaney, S.L., Murray, L.A., Fallon, B.A. (2022). Neuropsychiatric Symptoms and Tick-Borne Diseases. In: Savitz, J., Yolken, R.H. (eds) Microorganisms and Mental Health. Current Topics in Behavioral Neurosciences, vol 61. Springer, Cham. https://doi.org/10.1007/7854_2022_406
Download citation
DOI: https://doi.org/10.1007/7854_2022_406
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-24332-5
Online ISBN: 978-3-031-24333-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)